ABT-288
- Generic Name
- ABT-288
- Drug Type
- Small Molecule
- Chemical Formula
- C23H24N4O
- CAS Number
- 948845-91-8
- Unique Ingredient Identifier
- 5MEI1M3NHH
- Background
ABT-288 is under investigation in clinical trial NCT01018875 (Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease).
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia
Phase 2
Completed
- Conditions
- Cognitive Deficits in Schizophrenia
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 214
- Registration Number
- NCT01077700
- Locations
- 🇺🇸
Site Reference ID/Investigator# 21584, Pico Rivera, California, United States
🇺🇸Site Reference ID/Investigator# 21681, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 45310, Norwalk, California, United States
Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2009-11-24
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 242
- Registration Number
- NCT01018875
- Locations
- 🇺🇦
Site Reference ID/Investigator# 24565, Kherson, Ukraine
🇷🇺Site Reference ID/Investigator# 22636, Moscow, Russian Federation
🇷🇺Site Reference ID/Investigator# 22635, St. Petersburg, Russian Federation
A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 81
- Registration Number
- NCT00888693
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath